Article Information
History
- April 7, 2022.
Article Versions
- Version 1 (March 31, 2022 - 19:48).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ruth Y. Eberhardt1,
- Caroline F. Wright3,
- David R. FitzPatrick4,
- Matthew E. Hurles1 and
- Helen V. Firth1,2,*
- 1Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, Hinxton CB10 1SA, UK
- 2East Anglian Medical Genetics Service, Box 134, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
- 3University of Exeter Medical School, Institute of Biomedical and Clinical Science, Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK
- 4MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, WGH, Edinburgh EH4 2SP, UK
- ↵*Corresponding author: Helen V. Firth, hvf21{at}cam.ac.uk
Posted April 07, 2022.
Detection of mosaic chromosomal alterations in children with severe developmental disorders recruited to the DDD study
